WO2004031409A3 - Method for diagnosing chronic myeloid leukemia - Google Patents

Method for diagnosing chronic myeloid leukemia Download PDF

Info

Publication number
WO2004031409A3
WO2004031409A3 PCT/JP2003/010256 JP0310256W WO2004031409A3 WO 2004031409 A3 WO2004031409 A3 WO 2004031409A3 JP 0310256 W JP0310256 W JP 0310256W WO 2004031409 A3 WO2004031409 A3 WO 2004031409A3
Authority
WO
WIPO (PCT)
Prior art keywords
cml
myeloid leukemia
chronic myeloid
diagnosing chronic
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2003/010256
Other languages
French (fr)
Other versions
WO2004031409A2 (en
Inventor
Yusuke Nakamura
Toyomasa Katagiri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncotherapy Science Inc
University of Tokyo NUC
Original Assignee
Oncotherapy Science Inc
University of Tokyo NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc, University of Tokyo NUC filed Critical Oncotherapy Science Inc
Priority to AU2003253439A priority Critical patent/AU2003253439A1/en
Priority to JP2004541212A priority patent/JP2006500944A/en
Priority to US10/529,833 priority patent/US20070092519A1/en
Priority to CA002500470A priority patent/CA2500470A1/en
Priority to EP03799079A priority patent/EP1546409A2/en
Publication of WO2004031409A2 publication Critical patent/WO2004031409A2/en
Publication of WO2004031409A3 publication Critical patent/WO2004031409A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Objective methods for detecting and diagnosing Chronic myeloid leukemia (CML) are described herein. In one embodiment, the diagnostic method involves the determining a expression level of CML-associated gene that discriminate between CML and nomal cell. The present invention further provides methods of screening for therapeutic agents useful in the treatment of CML, methods of treating CML and method of vaccinating a subject against CML.
PCT/JP2003/010256 2002-09-30 2003-08-12 Method for diagnosing chronic myeloid leukemia Ceased WO2004031409A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2003253439A AU2003253439A1 (en) 2002-09-30 2003-08-12 Method for diagnosing chronic myeloid leukemia
JP2004541212A JP2006500944A (en) 2002-09-30 2003-08-12 How to diagnose chronic myeloid leukemia
US10/529,833 US20070092519A1 (en) 2002-09-30 2003-08-12 Method for diagnosing chronic myeloid leukemia
CA002500470A CA2500470A1 (en) 2002-09-30 2003-08-12 Method for diagnosing chronic myeloid leukemia
EP03799079A EP1546409A2 (en) 2002-09-30 2003-08-12 Method for diagnosing chronic myeloid leukemia

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41486702P 2002-09-30 2002-09-30
US60/414,867 2002-09-30

Publications (2)

Publication Number Publication Date
WO2004031409A2 WO2004031409A2 (en) 2004-04-15
WO2004031409A3 true WO2004031409A3 (en) 2005-02-24

Family

ID=32069778

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/JP2003/009589 Ceased WO2004031237A1 (en) 2002-09-30 2003-07-29 Genes and polypeptides relating to human myeloid leukemia
PCT/JP2003/010256 Ceased WO2004031409A2 (en) 2002-09-30 2003-08-12 Method for diagnosing chronic myeloid leukemia

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/JP2003/009589 Ceased WO2004031237A1 (en) 2002-09-30 2003-07-29 Genes and polypeptides relating to human myeloid leukemia

Country Status (7)

Country Link
US (1) US20070092519A1 (en)
EP (2) EP1549676A1 (en)
JP (2) JP2006517783A (en)
CN (1) CN100434439C (en)
AU (2) AU2003249012A1 (en)
CA (2) CA2500405A1 (en)
WO (2) WO2004031237A1 (en)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7259150B2 (en) 2001-08-07 2007-08-21 Isis Pharmaceuticals, Inc. Modulation of apolipoprotein (a) expression
WO2006006948A2 (en) 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
US9879266B2 (en) 2002-11-14 2018-01-30 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US9719094B2 (en) 2002-11-14 2017-08-01 Thermo Fisher Scientific Inc. RNAi targeting SEC61G
US7635770B2 (en) 2002-11-14 2009-12-22 Dharmacon, Inc. siRNA targeting protein kinase N-3 (PKN-3)
US9719092B2 (en) 2002-11-14 2017-08-01 Thermo Fisher Scientific Inc. RNAi targeting CNTD2
US7619081B2 (en) 2002-11-14 2009-11-17 Dharmacon, Inc. siRNA targeting coatomer protein complex, subunit beta 2 (COPB2)
US10011836B2 (en) 2002-11-14 2018-07-03 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US8198427B1 (en) 2002-11-14 2012-06-12 Dharmacon, Inc. SiRNA targeting catenin, beta-1 (CTNNB1)
US7951935B2 (en) 2002-11-14 2011-05-31 Dharmacon, Inc. siRNA targeting v-myc myelocytomatosis viral oncogene homolog (MYC)
US7977471B2 (en) 2002-11-14 2011-07-12 Dharmacon, Inc. siRNA targeting TNFα
US9228186B2 (en) 2002-11-14 2016-01-05 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US7781575B2 (en) 2002-11-14 2010-08-24 Dharmacon, Inc. siRNA targeting tumor protein 53 (p53)
US7612196B2 (en) 2002-11-14 2009-11-03 Dharmacon, Inc. siRNA targeting cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B)
US9839649B2 (en) 2002-11-14 2017-12-12 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
AU2003295600A1 (en) 2002-11-14 2004-06-15 Dharmacon, Inc. Functional and hyperfunctional sirna
US7592442B2 (en) 2002-11-14 2009-09-22 Dharmacon, Inc. siRNA targeting ribonucleotide reductase M2 polypeptide (RRM2 or RNR-R2)
US7691998B2 (en) 2002-11-14 2010-04-06 Dharmacon, Inc. siRNA targeting nucleoporin 62kDa (Nup62)
US9771586B2 (en) 2002-11-14 2017-09-26 Thermo Fisher Scientific Inc. RNAi targeting ZNF205
US7605250B2 (en) 2004-05-12 2009-10-20 Dharmacon, Inc. siRNA targeting cAMP-specific phosphodiesterase 4D
ES2315040B2 (en) * 2004-11-22 2009-10-16 Universidad De Cantabria PROCEDURE TO DETERMINE THE EFFECTIVENESS OF THE TREATMENT AND THE PROGRESSION DEGREE OF CHRONIC MYELOID LEUKEMIA BY USING SPI-1 / PI.1.
TWI386225B (en) * 2004-12-23 2013-02-21 Alcon Inc Rnai inhibition of ctgf for treatment of ocular disorders
CN100347299C (en) * 2005-02-04 2007-11-07 上海第二医科大学附属瑞金医院 GATA-2 mutator as one of leukemia rapid change major genes and its use
CA2597845A1 (en) 2005-02-25 2006-08-31 Isis Pharmaceuticals, Inc. Compositions and their uses directed to il-4r alpha
US7825099B2 (en) * 2006-01-20 2010-11-02 Quark Pharmaceuticals, Inc. Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes
US7910566B2 (en) 2006-03-09 2011-03-22 Quark Pharmaceuticals Inc. Prevention and treatment of acute renal failure and other kidney diseases by inhibition of p53 by siRNA
WO2007141796A2 (en) * 2006-06-09 2007-12-13 Quark Pharmaceuticals, Inc. Therapeutic uses of inhibitors of rtp801l
WO2009001359A2 (en) 2007-06-27 2008-12-31 Quark Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of pro-apoptotic genes
TW200920406A (en) * 2007-08-24 2009-05-16 Oncotherapy Science Inc EBI3, DLX5, NPTX1 and CDKN3 for target genes of lung cancer therapy and diagnosis
WO2010007464A1 (en) * 2008-07-18 2010-01-21 Centre National De La Recherche Scientifique USE OF DEFENSIN α1 AND/OR DEFENSIN α4, AS A MARKER FOR PREDICTING A RELAPSE IN A PATIENT SUFFERING FROM CHRONIC MYELOID LEUKAEMIA
US20160002624A1 (en) 2012-05-17 2016-01-07 Isis Pharmaceuticals, Inc. Antisense oligonucleotide compositions
US9574193B2 (en) 2012-05-17 2017-02-21 Ionis Pharmaceuticals, Inc. Methods and compositions for modulating apolipoprotein (a) expression
WO2014110506A2 (en) 2013-01-14 2014-07-17 The Trustees Of Columbia University In The City Of New York Methods of treating, preventing and diagnosing leukemia and other blood diseases and disorders
KR101710745B1 (en) * 2013-07-16 2017-02-27 가천대학교 산학협력단 Composition for diagnosis of leukemia
CN103937901B (en) * 2014-05-06 2015-02-25 北京大学第一医院 Primers and kit for detecting specific gene HB-1 of acute B lymphocyte leukemia
CN106471130A (en) * 2014-05-09 2017-03-01 杰克逊实验室 Identification changes method of compound of iRhom polypeptide active and application thereof
KR101865198B1 (en) * 2016-04-08 2018-06-08 충남대학교산학협력단 Method for providing the information for chronic myeloid leukemia
CA3066738A1 (en) * 2017-06-15 2018-12-20 The University Of Chicago Methods and compositions for treating cancer
EP4197552A1 (en) 2018-03-12 2023-06-21 The Children's Hospital of Philadelphia Methods and compositions for use of tumor self-antigens in adoptive immunotherapy
WO2019238966A1 (en) * 2018-06-15 2019-12-19 Universität Bern LIGANDS TO LIGHT OR ITS RECEPTOR LTßR FOR USE IN HAEMATOLOGIC MALIGNANCIES
US12516307B2 (en) 2020-08-18 2026-01-06 Onchilles Pharma, Inc. Modified porcine pancreatic elastase proteins
CN113373218A (en) * 2021-08-04 2021-09-10 杭州浙大迪迅生物基因工程有限公司 Primer group and kit for detecting mRNA expression of human eosinophil cationic protein
CN114507736A (en) * 2022-03-07 2022-05-17 河南省肿瘤医院 Application of TCF1-IRF4 in preparation of kit for predicting CLL disease prognosis
CN115820855B (en) * 2022-10-12 2023-07-21 南昌大学第二附属医院 Application of HDC, SMPDL3A, IRF4 and AQP3 in the preparation of reagents and kits for diagnosing CML

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997046885A1 (en) * 1996-06-06 1997-12-11 Pharmacia & Upjohn Ab DIAGNOSTIC METHOD FOR DETECTION OF MOLECULAR FORMS OF EOSINOPHILIC CATIONIC PROTEIN (iso-ECPs)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69602756T2 (en) * 1995-08-18 2000-02-10 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Rockville FUNCTIONAL ROLE OF ADRENOMEDULLIN (AM) AND THE GENE-RELATED PRODUCT (PAMP) IN HUMAN PATHOLOGY AND PHYSIOLOGY
AU2001276967A1 (en) * 2000-07-19 2002-01-30 Exelixis, Inc. Human RRP sequences and methods of use
US20050037445A1 (en) * 2001-06-25 2005-02-17 Poulsen Hans Skovgaard Oncology drug innovation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997046885A1 (en) * 1996-06-06 1997-12-11 Pharmacia & Upjohn Ab DIAGNOSTIC METHOD FOR DETECTION OF MOLECULAR FORMS OF EOSINOPHILIC CATIONIC PROTEIN (iso-ECPs)

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
COHEN N ET AL: "Subgroup of patients with Philadelphia-positive chronic myelogenous leukemia characterized by a deletion of 9q proximal to ABL gene: expression profiling, resistance to interferon therapy, and poor prognosis.", CANCER GENETICS AND CYTOGENETICS. UNITED STATES 15 JUL 2001, vol. 128, no. 2, 15 July 2001 (2001-07-15), pages 114 - 119, XP002261372, ISSN: 0165-4608 *
DATABASE EMBL [online] 10 August 1993 (1993-08-10), XP002261375, retrieved from EBI Database accession no. X16545 *
DELILIERS GIORGIO LAMBERTENGHI ET AL: "Effect of inositol hexaphosphate (IP(6)) on human normal and leukaemic haematopoietic cells.", BRITISH JOURNAL OF HAEMATOLOGY. ENGLAND JUN 2002, vol. 117, no. 3, June 2002 (2002-06-01), pages 577 - 587, XP002261371, ISSN: 0007-1048 *
KANETA YASUYUKI ET AL: "Prediction of sensitivity to STI571 among chronic myeloid leukemia patients by genome-wide cDNA microarray analysis.", JAPANESE JOURNAL OF CANCER RESEARCH: GANN. JAPAN AUG 2002, vol. 93, no. 8, August 2002 (2002-08-01), pages 849 - 856, XP002260979, ISSN: 0910-5050 *
LI HUIYU ET AL: "CDNA microarray analysis of chronic myeloid leukemia.", INTERNATIONAL JOURNAL OF HEMATOLOGY. IRELAND MAY 2002, vol. 75, no. 4, May 2002 (2002-05-01), pages 388 - 393, XP009020831, ISSN: 0925-5710 *
MAEDA TAKASHI ET AL: "Growth inhibition of mammalian cells by eosinophil cationic protein.", EUROPEAN JOURNAL OF BIOCHEMISTRY / FEBS. GERMANY JAN 2002, vol. 269, no. 1, January 2002 (2002-01-01), pages 307 - 316, XP002261370, ISSN: 0014-2956 *
MIYAZATO A ET AL: "IDENTIFICATION OF MYELODYSPLASTIC SYNDROME-SPECIFIC GENES BY DNA MICROARRAY ANALYSIS WITH PURIFIED HEMATOPOIETIC STEM CELL FRACTION", BLOOD, W.B.SAUNDERS COMPAGNY, ORLANDO, FL, US, vol. 98, no. 2, 15 July 2001 (2001-07-15), pages 422 - 427, XP002952629, ISSN: 0006-4971 *
MUKAI H Y ET AL: "Elevated serum levels of eosinophil major basic protein in patients with myeloproliferative disorders without eosinophilia.", INTERNATIONAL JOURNAL OF HEMATOLOGY. IRELAND AUG 1997, vol. 66, no. 2, August 1997 (1997-08-01), pages 197 - 202, XP009021081, ISSN: 0925-5710 *
NOWICKI MICHAL OSKAR ET AL: "Chronic myelogenous leukemia molecular signature.", ONCOGENE. ENGLAND 19 JUN 2003, vol. 22, no. 25, 19 June 2003 (2003-06-19), pages 3952 - 3963, XP002261374, ISSN: 0950-9232 *
OHMINE K ET AL: "CHARACTERIZATION OF STAGE PROGRESSION IN CHRONIC MYELOID LEUKEMIA BY DNA MICROARRAY WITH PURIFIED HEMATOPOIETIC STEM CELLS", ONCOGENE, BASINGSTOKE, HANTS, GB, vol. 20, no. 57, 2001, pages 8249 - 8257, XP002952628, ISSN: 0950-9232 *
QIAN ZHIJIAN ET AL: "Expression profiling of CD34+ hematopoietic stem/ progenitor cells reveals distinct subtypes of therapy-related acute myeloid leukemia.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. UNITED STATES 12 NOV 2002, vol. 99, no. 23, 12 November 2002 (2002-11-12), pages 14925 - 14930, XP002261373, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
CA2500470A1 (en) 2004-04-15
EP1546409A2 (en) 2005-06-29
AU2003249012A8 (en) 2004-04-23
AU2003249012A1 (en) 2004-04-23
JP2006500944A (en) 2006-01-12
CN100434439C (en) 2008-11-19
EP1549676A1 (en) 2005-07-06
WO2004031237A1 (en) 2004-04-15
US20070092519A1 (en) 2007-04-26
CN1701079A (en) 2005-11-23
AU2003253439A8 (en) 2004-04-23
CA2500405A1 (en) 2004-04-15
WO2004031409A2 (en) 2004-04-15
AU2003253439A1 (en) 2004-04-23
JP2006517783A (en) 2006-08-03

Similar Documents

Publication Publication Date Title
WO2004031409A3 (en) Method for diagnosing chronic myeloid leukemia
WO2004031410A3 (en) Method for diagnosing testicular seminomas
EP2009117A3 (en) Method for diagnosing pancreatic cancer
WO2005028676A3 (en) Method of diagnosing breast cancer
WO2004031414A3 (en) Method for diagnosing prostate cancer
WO2003073910A3 (en) Assays for cancer patient monitoring based on levels of analyte components of the plasminogen activator system in body fluid samples
WO2007013575A3 (en) Method for diagnosing and treating renal cell carcinoma
AU2002366641A1 (en) Methods for inhibiting ocular processes
WO2004007770A3 (en) Method for diagnosis of intestinal-type gastric tumors
WO2008140774A3 (en) Methods for diagnosing and treating prostate and lung cancer
WO2004021010A3 (en) Method of diagnosing colon and gastric cancers
EP1310797A3 (en) Method of monitoring neuroprotective treatment
WO2002063005A3 (en) Lipid-associated molecules
WO2004038045A3 (en) Method for diagnosing diffuse-type gastric cancer
WO2004045376A3 (en) Screening methods to identify treatments for autoimmune disease
AU1855401A (en) Screening method for candidate drugs
WO2006059252A3 (en) Methods and fluorinated compositions for treating amyloid-related diseases
WO2006068758A3 (en) Detection, prevention and treatment of breast cancer
WO2007013360A3 (en) Pancreatic cancer related gene cst6 and gabrp
SG163614A1 (en) Colon cancer related gene tom34
WO2001098471A3 (en) Human phosphodiesterases
WO2004071465A3 (en) Methods and kits for use in the diagnosis and treatment of endotoxemia
WO2004039312A3 (en) Optineurin and glaucoma
WO2001004343A3 (en) A method for determining the prognosis of cancer patients by measuring levels of bag expression
WO2005083118A3 (en) Pin-prc transition genes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004541212

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2500470

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003799079

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003799079

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007092519

Country of ref document: US

Ref document number: 10529833

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10529833

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2003799079

Country of ref document: EP